Importantly, targeting cancer-specific splice variations or depletion of Ciz1 by siRNA reduced tumor growth in xenograft models, identifying a potentially selective therapeutic avenue to reduce tumor proliferation [73,74,77,78,79,80,81]. Here, CIZ1 is linked to cancer.